» Articles » PMID: 38821052

Deletion of the MRNA Endonuclease Regnase-1 Promotes NK Cell Anti-tumor Activity Via OCT2-dependent Transcription of Ifng

Overview
Journal Immunity
Publisher Cell Press
Date 2024 May 31
PMID 38821052
Authors
Affiliations
Soon will be listed here.
Abstract

Limited infiltration and activity of natural killer (NK) and T cells within the tumor microenvironment (TME) correlate with poor immunotherapy responses. Here, we examined the role of the endonuclease Regnase-1 on NK cell anti-tumor activity. NK cell-specific deletion of Regnase-1 (Reg1) augmented cytolytic activity and interferon-gamma (IFN-γ) production in vitro and increased intra-tumoral accumulation of Reg1-NK cells in vivo, reducing tumor growth dependent on IFN-γ. Transcriptional changes in Reg1-NK cells included elevated IFN-γ expression, cytolytic effectors, and the chemokine receptor CXCR6. IFN-γ induced expression of the CXCR6 ligand CXCL16 on myeloid cells, promoting further recruitment of Reg1-NK cells. Mechanistically, Regnase-1 deletion increased its targets, the transcriptional regulators OCT2 and IκBζ, following interleukin (IL)-12 and IL-18 stimulation, and the resulting OCT2-IκBζ-NF-κB complex induced Ifng transcription. Silencing Regnase-1 in human NK cells increased the expression of IFNG and POU2F2. Our findings highlight NK cell dysfunction in the TME and propose that targeting Regnase-1 could augment active NK cell persistence for cancer immunotherapy.

Citing Articles

Cancer phenomics research hotspots and development trends: a bibliometric analysis from 2000 to 2023.

Chen S, Liu J, Tang N, Zeng Y Discov Oncol. 2024; 15(1):811.

PMID: 39695032 PMC: 11655722. DOI: 10.1007/s12672-024-01710-w.


Targeting metabolic dysfunction of CD8 T cells and natural killer cells in cancer.

Viel S, Vivier E, Walzer T, Marcais A Nat Rev Drug Discov. 2024; 24(3):190-208.

PMID: 39668206 DOI: 10.1038/s41573-024-01098-w.


The Nuclear NF-κB Regulator IκBζ: Updates on Its Molecular Functions and Pathophysiological Roles.

Yamazaki S Cells. 2024; 13(17.

PMID: 39273036 PMC: 11393961. DOI: 10.3390/cells13171467.


Engineering NK cells with LNP-enabled IL-2 mRNA transfection: Steps toward affordable precision immuno-therapeutics.

Mahalingam G, Tandel N, Tyagi R, Marepally S Mol Ther Nucleic Acids. 2024; 35(3):102276.

PMID: 39176176 PMC: 11338940. DOI: 10.1016/j.omtn.2024.102276.